Abstract:Yingfeng Tu, 1, 2 Xiaowei Ma, 3 Hao Chen, 2, 4 Yuhua Fan, 5 Lei Jiang, 2 Ruiping Zhang, 2, 6 Zhen Cheng 2, 4 1 Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China; 2 Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Stanford University, Stanford, CA, USA; 3 Department of Nuclear Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; 4 Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China; 5 College of Pharmacy, Harbin Medical University, Daqing, Heilongjiang, People's Republic of China; 6 The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, People's Republic of China Correspondence: Zhen Cheng, Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, 1201 Welch Road, Lucas Expansion, P095, Stanford University, Stanford, CA, 94305, USA, Tel +01-650-723-7866, Email Ruiping Zhang, Department of Radiology, the Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, People's Republic of China, Email Background: Matrix metalloproteinases from macrophages are important intraplaque components that play pivotal roles in plaque progression and regression. This study sought to develop a novel multifunctional positron emission tomography (PET) and magnetic resonance imaging (MRI) contrast agents based on MMP-2 cleavable nanoparticles to noninvasive assessment of MMP-2 activity in mouse carotid atherosclerotic plaques. Results: Macrophage-rich vascular lesions were induced by carotid ligation plus high-fat diet and streptozotocin-induced diabetes in CL57/BL6 mice. To render iron oxide nanoparticles (IONP) specific for the extracellular MMP-2, the magnetic nanoparticle base material has been derivatized with 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) for the nuclear tracer 64 Cu labeling and the MMP-2-cleavable peptide modified with polyethylene glycol 2000, yielding a multi-modality reporter ( 64 , MMP2cNPs) for PET/MR imaging. Small animal PET imaging and biodistribution data revealed that MMP2cNPs exhibited remarkable plaque uptake (3.06 ± 0.87% ID/g and 1.83 ± 0.28% ID/g at 4 and 12 h, respectively). And MMP2cNPs were rapidly cleared from the contralateral normal carotid artery, resulting in excellent plaque-to-normal carotid artery contrasts. Furthermore, in vivo MRI showed a preferential accumulation of MMP2cNPs in atherosclerotic lesions compared with the non-cleavable reference compound, MMP2ncNPs. In addition, histological analyses revealed iron accumulations in the carotid atherosclerotic plaque, in colocalization with MMP-2 expression and macrophages. Conclusion: Using a combination of innovative imaging modalities, in this study, we demonstrate the feasibility of applying the novel smart MMP2cNPs as a PET/MR hybrid imaging contrast agent for detection of MMP-2 in atherosclerotic plaque in vivo. Graphical Keywords: atherosclerosis, macrophage, matrix metalloproteinase-2, nanoparticles, magnetic resonance imaging, positron emission tomography Graphical Despite current optimal treatment, atherosclerosis diseases are still the leading cause of death all over the world. 1 Nowadays, there has been a shift in emphasis from treatment of atherosclerosis diseases to the primary or secondary prevention of diseases. Furthermore, advances in atherosclerotic plaque biology have translated into the discovery of novel therapies, which in turn have led to a reduction in morbidity and mortality. However, this shift puts forward new challenges to basic research as well as to clinical practice and further stimulates technological revolution of existing imaging diagnostic methods. In recent years, nanotechnology is emerging as a new field of interdisciplinary research, cutting across the disciplines of materialogy, biology, chemistry, engineering, and medicine, which is expected to lead to major advances in atherosclerosis detection, diagnosis, and clinical treatment. 2–5 As potentially powerful probes, nanoparticles (NPs) have been widely applied to molecular imaging in biological and clinical diagnostics, 5–7 which are generally believed to revolutionize clinical bioimaging techniques in cardiovascular diseases, especially in atherosclerosis. Infla -Abstract Truncated-

Development of Nuclide Targeted Matrix Metalloproteinase Inhibitors in Atherosclerotic Plaque Imaging

Metastatic Melanoma Targeting Property of a Novel Tc-99m-labeled HYNIC-conjugated Lactam Bridge-Cyclized Alpha-Msh Peptide

Molecular Imaging of Matrix Metalloproteinases in Vulnerable Plaque in Atherosclerosis

Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability

Synthesis and Biodistribution of 99Mtc(co)3-Cpadg As a Promising Tumor Imaging Agent

99Mtc(co)3-Labeled 2-Phenylbenzothiazoles As Aβ Imaging Agents for the Detection of CAA

Abstract 272: Targeted Activatable Cell-Penetrating Peptides Identify Atherosclerotic Plaques in Mice with Noninvasive Magnetic Resonance Imaging

Multifunctional pathology-mapping theranostic nanoplatforms for US/MR imaging and ultrasound therapy of atherosclerosis

Molecular Imaging of Matrix Metalloproteinase-2 in Atherosclerosis Using a Smart Multifunctional PET/MRI Nanoparticle

Molecular imaging of MMP activity discriminates unstable from stable plaque phenotypes in shear-stress induced murine atherosclerosis

Selective Imaging of Matrix Metalloproteinase-13 to Detect Extracellular Matrix Remodeling in Atherosclerotic Lesions

Evaluation of a Smart Activatable MRI Nanoprobe to Target Matrix Metalloproteinases in the Early-Stages of Abdominal Aortic Aneurysms.

Temporal and Quantitative Analysis of Expression of Metalloproteinases (mmps) and Their Endogenous Inhibitors in Atherosclerotic Lesions.

MMP-14-Targeted Nanoprobe for in Vivo Fluorescence Imaging of Rupture-Prone Carotid Plaques

P1216Evaluation of Alphavbeta3 Integrin-Targeted Positron Emission Tomography and Photoacoustic Tracer for Imaging of Carotid Plaque in Apoe–/– Mice

Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs)

Precise theranostic nanomedicines for inhibiting vulnerable atherosclerotic plaque progression through regulation of vascular smooth muscle cell phenotype switching

Recent Advances in Molecular Imaging of Atherosclerotic Plaques and Thrombosis

Current Development of Molecular Coronary Plaque Imaging using Magnetic Resonance Imaging towards Clinical Application

Matrix Metalloproteinase-Targeted SPECT/CT Imaging for Evaluation of Therapeutic Hydrogels for the Early Modulation of Post-Infarct Myocardial Remodeling

Research progress of nuclear medicine imaging in detection of vulnerable atherosclerotic plaques